FDA approves Avatar Medical’s 3D image processing software
April 29, 2026
Avatar’s software translates CT and MR imaging data into 3D images to streamline surgical planning and operating room workflows.
Avatar’s software translates CT and MR imaging data into 3D images to streamline surgical planning and operating room workflows.
Researchers at McGill University have developed a rapid way to engineer blood clots that stop severe bleeding and support tissue healing more effectively.
A pharmaceutical research team has identified a natural compound, timosaponin AIII (TAIII), that selectively eliminates CAR-T regulatory T cells.
Researchers at Karolinska Institutet, in collaboration with colleagues at The Scripps Research Institute and Emory University, have developed a new vaccine strategy that has generated antibodies capable of neutralizing highly divergent HIV variants.
Medtronic (NYSE:MDT) announced today that it received FDA approval for its Mosaic Neo mitral bioprosthesis and began its U.S. launch.
Earflo announced that it received FDA clearance for its non-invasive device designed to treat negative middle ear pressure in children.
In a study published in the New England Journal of Medicine, researchers at UC San Francisco and UC Irvine show the device is as effective as a laboratory test and can detect cases even among people who have trouble producing phlegm samples from deep within their lungs.
Researchers at Johns Hopkins Medicine say they have successfully demonstrated that disrupting an eye structure long suspected of blocking the growth and survival of transplanted nerve cells may help restore vision in people with optic nerve damage.
Researchers developed the Cardiac Autoregressive Model for ECG Language-Modeling (CAMEL), an artificial intelligence model that treats ECG less like isolated snapshots and more like language.
Researchers developed a “tumor-on-a-chip” system designed to recreate that environment outside the human body, offering a more realistic way to study the disease and evaluate treatments.